TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03254628

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Helping Mothers Survive - Bleeding After Birth training
Description: One-day training in postpartum hemorrhage prevention and treatment; this includes instruction to provide oxytocin within one minute of birth to prevent postpartum hemorrhage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helping Mothers Survive - Bleeding After Birth training
Description: One-day training in postpartum hemorrhage prevention and treatment; this includes instruction to provide oxytocin within one minute of birth to prevent postpartum hemorrhage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helping Mothers Survive - Bleeding After Birth training
Description: One-day training in postpartum hemorrhage prevention and treatment; this includes instruction to provide oxytocin within one minute of birth to prevent postpartum hemorrhage.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Helping Babies Breathe
Description: One-day training in neonatal asphyxia management; this includes routine care for the newborn, such as drying and stimulation immediately after birth, and resuscitation of asphyxiated newborns using a bag \& mask device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helping Babies Breathe
Description: One-day training in neonatal asphyxia management; this includes routine care for the newborn, such as drying and stimulation immediately after birth, and resuscitation of asphyxiated newborns using a bag \& mask device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helping Babies Breathe
Description: One-day training in neonatal asphyxia management; this includes routine care for the newborn, such as drying and stimulation immediately after birth, and resuscitation of asphyxiated newborns using a bag \& mask device.
Study: NCT05002062

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RehaCom computer-based cognitive training in addition to Conventional physical therapy program
Description: Rehacom procedure: It is a computer-based intensive cognitive rehabilitation test used to assess patient's cognitive functions. It includes 32 assessment tasks for attention, memory , logical reasoning\& executive functioning. It composes of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel \& printer .The Rehacom software version is (patient enpult (1990-1997) EN/ISO-13485-certified). It is characterized by easy handling, close to reality , motivating for patients.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional physical therapy program
Description: Conventional physical therapy program for MS patients include aerobic training, resistive training and flexibility program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy program
Description: Conventional physical therapy program for MS patients include aerobic training, resistive training and flexibility program
Study: NCT00523016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP)
Description: LCCNPAP: acupuncture needle insertion at acupuncture points on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture: Simulated acupuncture that includes insertion of acupuncture needles on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
Study: NCT01722084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theory of planned behaviour (TPB) and social cognitive theory (SCT).
Description: TPB is appropriate to influence adolescents' behaviour related to the use of contraceptive methods and their health/information seeking behaviour. The SCT helped to find out strategies to improve communication about sexuality, to promote openness towards adolescents' sexuality among parents, community members and health providers and for health providers to adopt a more adolescent friendly attitude.The development of the strategies in the different countries is a dynamic process that is continuously being adapted. The target groups were driving the process of identifying, selecting and implementing interventions. Therefore, local institutions were involved in the intervention. Attention was paid to ensure that the interventions were in line with the existing local structures/policies and reinforce the local health system.Primary health care services had a key role in the interventions. Gender was a transversal topic throughout the intervention process.
Study: NCT01785693

Intervention type: DRUG
Group type: OTHER
Intervention: levobupivacaine, clonidine

Intervention type: DRUG
Group type: OTHER
Intervention: levobupivacaine, clonidine
Study: NCT01631981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL2001 + Primolut-Nor 5
Description: PGL2001(estradiol sulfamate, E2MATE, ZK190628), Tablets, 1mg. 4 mg weekly for 4 weeks followed by 2mg weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg. Once daily for 16 weeks plus during follow-up.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Primolut-Nor 5
Description: Placebo, Tablets.4 tablets weekly for 4 weeks followed by 2 tablets weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg.Once daily for 16 weeks plus during follow-up.
Study: NCT01816282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evicel
Description: Evicel (5ml) is sprayed over the soft tissue after the implant of prosthetic components and before wounding closure
Study: NCT03895541

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SuperSonic image
Description: 3 examen performed assessed to compared evaluation type: Cardiac magnetic resonance imaging, standard ultrasound imaging and ultrafast imaging
Study: NCT00950105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPSI-2364 or placebo
Description: Single, oral dose of CPSI-2364 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPSI-2364 or placebo
Description: Single, oral dose of CPSI-2364 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPSI-2364 or placebo
Description: Single, oral dose of CPSI-2364 or placebo
Study: NCT03254628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentor
Description: A birth attendant in the facility is designated as a clinical mentor and encouraged to lead simulator-based practice sessions in the facility after training day.
Study: NCT00950105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPSI-2364 or placebo
Description: Single, oral dose of CPSI-2364 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPSI-2364 or placebo
Description: Single, oral dose of CPSI-2364 or placebo
Study: NCT03254628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentor
Description: A birth attendant in the facility is designated as a clinical mentor and encouraged to lead simulator-based practice sessions in the facility after training day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone
Description: District trainers telephone clinical mentors and encourage them to lead practice sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin and misoprostol
Description: This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.
Study: NCT03254628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin and misoprostol
Description: This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin and misoprostol
Description: This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Newborn bag and mask
Description: All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Newborn bag and mask
Description: All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Newborn bag and mask
Description: All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care
Study: NCT01234480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD SurePath Plus Pap test
Description: BD SurePath Plus Pap test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD SurePath Plus Pap test
Description: BD SurePath Plus Pap test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD SurePath Pap test
Description: BD SurePath Plus Pap test
Study: NCT02531204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP1585
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: oral
Study: NCT04316065

Intervention type: DRUG
Group type: OTHER
Intervention: YHP1906
Description: YHP1906 Tab. 5 mg

Intervention type: DRUG
Group type: OTHER
Intervention: YHP1906
Description: YHP1906 Tab. 5 mg

Intervention type: DRUG
Group type: OTHER
Intervention: YHR1902
Description: Comparator. YHR1902 Tab. 5 mg

Intervention type: DRUG
Group type: OTHER
Intervention: YHR1902
Description: Comparator. YHR1902 Tab. 5 mg
Study: NCT00589251

Intervention type: OTHER
Group type: OTHER
Intervention: penicillin skin test
Description: Prick skin tests will be performed on the volar surface of the forearm with each penicilloate and control reagents. The skin test sites will be examined at 15 minutes. A positive test result is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. Patients with negative prick test results to penicillin will undergo intradermal testing.~Intradermal skin tests will be performed on the volar surface of the forearm. The test reagents will be injected intradermally to produce an initial wheal of 2x2 mm. The skin test sites will be examined at 15 minutes. A positive intradermal test is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. In order to ensure patient safety, we will consider using an end point titration technique.
Study: NCT02080234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GELOX
Description: gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IFRT
Description: IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions
Study: NCT01540240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Low dosage AZT arm: AZT 200 mg/3TC 150 mg(zidovudine 100 mg 2 caps/lamivudine 150 mg 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
Study: NCT00003211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study: NCT03934203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet
Study: NCT00003211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Study: NCT03934203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet
Study: NCT00003211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01234480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD SurePath Pap test
Description: BD SurePath Plus Pap test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colposcopy with biopsy/ECC
Description: Colposcopy with biopsy/ECC for subjects with 1)BD SurePath Pap NILM, but HPV positive, or 2) BD SurePath Plus Pap test result of ASC-US or higher 3)BD SurePath Pap ASC-US or higher

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPV DNA test
Description: digene HC2 HPV DNA test
Study: NCT03934203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet
Study: NCT01234480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPV DNA test
Description: digene HC2 HPV DNA test
Study: NCT03934203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching to BI 409306
Description: Film-coated tablet
Study: NCT02104323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostatin
Description: Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Course of treatment: 3 months;Total three treatment courses.
Study: NCT03835013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Intravenous infusion of 0.9% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline 0.9%
Description: Intravenous infusion of 0.9% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline 0.9%
Description: Intravenous infusion of 0.9% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline 0.9%
Description: Intravenous infusion of 0.9% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline 0.9%
Description: Intravenous infusion of 0.9% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon (25ng/kg/min)
Description: Intravenous infusion of glucagon 25ng/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon (25ng/kg/min)
Description: Intravenous infusion of glucagon 25ng/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon (25ng/kg/min)
Description: Intravenous infusion of glucagon 25ng/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon (50ng/kg/min)
Description: Intravenous infusion of glucagon 50ng/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Intravenous infusion of Exenatide (loading 50ng/min for 30 minutes followed by 25ng/min for 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Intravenous infusion of Exenatide (loading 50ng/min for 30 minutes followed by 25ng/min for 30 minutes
Study: NCT01002898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir soft gel capsule
Description: Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.
Study: NCT02597491

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TLC monthly
Description: Tobacco longitudinal care monthly

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TLC monthly
Description: Tobacco longitudinal care monthly
Study: NCT02740699

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: Participants will receive 20-40 mg once daily
Study: NCT02597491

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TLC monthly
Description: Tobacco longitudinal care monthly
Study: NCT02740699

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: Participants will receive 40-80 mg once daily.
Study: NCT02740699

Intervention type: RADIATION
Group type: OTHER
Intervention: Cardiac Computed Tomography (CT)
Description: Cardiac CT angiography (CCTA) provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Performed at baseline, 12 months 24 months, and 36 months.
Study: NCT00003211

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02597491

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TLC quarterly
Description: Tobacco longitudinal care quarterly

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TLC quarterly
Description: Tobacco longitudinal care quarterly

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MTM
Description: Medication management therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MTM
Description: Medication management therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 week assessment
Description: 4 week assessment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 week assessment
Description: 4 week assessment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 week assessment
Description: 4 week assessment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 8 week assessment
Description: 8 week assessment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 8 week assessment
Description: 8 week assessment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 8 week assessment
Description: 8 week assessment
Study: NCT02740699

Intervention type: RADIATION
Group type: OTHER
Intervention: Cardiac Magnetic Resonance Image (MRI)
Description: Provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Cardiac MRI may be performed at baseline, and 24 months (optional).
Study: NCT01586650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: The intervention comprises fifty minutes of walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
Study: NCT01911078

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal Denervation
Description: Renal artery ablation with the EnligHTN™ Renal Denervation System.
Study: NCT01586650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Global stretching exercises will be performed for about 20 minutes 3 times a week for 12 weeks with supervision of specialized physiotherapists.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stretching exercises
Description: Global stretching exercises will be performed for about 20 minutes 3 times a week for 12 weeks with supervision of specialized physiotherapists.
Study: NCT01220713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 1.5 atm abs oxygen equivalent of 75% oxygen (balance 25% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 2.0 atm abs oxygen equivalent of 100% oxygen (no nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
Study: NCT03040739

Intervention type: OTHER
Intervention: use of O'ARM imaging system
Description: use of O'ARM imaging system

Intervention type: OTHER
Intervention: use of O'ARM imaging system
Description: use of O'ARM imaging system
Study: NCT04579406

Intervention type: PROCEDURE
Intervention: non-cardiac surgery
Description: All the patients are undergoing non-cardiac surgery.

Intervention type: PROCEDURE
Intervention: non-cardiac surgery
Description: All the patients are undergoing non-cardiac surgery.

Intervention type: PROCEDURE
Intervention: non-cardiac surgery
Description: All the patients are undergoing non-cardiac surgery.
Study: NCT00720356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10mg/kg administered intravenously every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 150 mg/daily orally
Study: NCT01220713

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: sham--air equivalent of 10.5% oxygen (balance 89.5% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.